Discovery of novel EGFR triple-mutation inhibitor with efficacy in preclinical models of NSCLC
July 24, 2023
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. presented the discovery and preclinical evaluation of novel EGFR(T790M/C797S) inhibitors for the treatment of mutant non-small-cell lung cancer (NSCLC).
